Anti-Andes Virus (Hantavirus) (Clone: ANDV-44)

Anti-Andes Virus (Hantavirus) (Clone: ANDV-44)

Product No.: LT551

- -
- -
Product No.LT551
Clone
ANDV-44
Target
Andes virus
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Hantavirus, Orthohantavirus, ANDV
Isotype
Human IgG1
Applications
ELISA
,
N

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Andes virus
Hantavirus
Virus
Expression Host
HEK-293 Cells
Immunogen
This human monoclonal antibody clone ANDV-44 was generated as part of a panel using a B cell hybridoma method from an individual previously infected with ANDV8.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Standard Overnight on Blue Ice.
Additional Applications Reported In Literature ?
ELISA
N: ANDV-44 shows neutralizing activity for ANDV, authentic Sin Nombre virus (SNV), cross-reactivity to SNV Gn and Gc proteins, and potent neutralizing activity to authentic OWH Hantaan virus strain 76–118.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone ANDV-44 competes for binding to a distinct site on the ANDV surface glycoprotein spike, a tetrameric complex composed of Gn and Gc envelope proteins8. Furthermore, antibody ANDV-44 recognizes antigenic site C1 but does not show reactivity to soluble Gc or Gn proteins and may bind to a target site only present in the quaternary spike structure.
Background
Hantavirus or Andes Virus is an enveloped, negative-sensed, single-stranded RNA virus in the bunyavirus family1. “New World” hantaviruses (NWH) are found in the Americas and may cause hantavirus pulmonary syndrome (HPS)2. “Old World” hantaviruses (OWH) are found mainly in Europe and Asia and may cause hemorrhagic fever with renal syndrome. Each hantavirus serotype has a specific rodent host species, and infection is spread primarily by aerosolized feces, urine, or saliva, with the exception of Andes Virus (ANDV) which is also capable of human-to-human transmission3,4.

ANDV, a NWH found in South America5, has a high fatality rate of up to 40%6. Clinical research shows that high titers of neutralizing antibodies in patient serum correlate with increased survival7, and monoclonal antibodies (mAbs), including ANDV-44, isolated from HPS survivors protect Syrian hamsters from ANDV postinfection6-8.

Antigen Details

Research Area
Andes
.
Category A Pathogens
.
Infectious Disease
.
Viral

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Link
2. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Link
3. Padula PJ, Edelstein A, Miguel SD, et al. Virology. 241:323–330. 1998.
4. Martinez VP, Bellomo C, San Juan J, et al. Emerg Infect Dis. 11:1848–1853. 2005.
5. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), https://www.cdc.gov/hantavirus/resources/andes-virus.html
6. Williamson BN, Prescott J, Garrido JL, et al. Emerg Infect Dis. 27(10):2707-2710. 2021.
7. Bharadwaj M, Nofchissey R, Goade D, et al. J Infect Dis. 182: 43–48. 2000.
8. Engdahl TB, Kuzmina NA, Ronk AJ, et al. Cell Rep. 35(5):109086. 2021.
9. Garrido, JL, et al. (2018) Sci Transl Med.10(468):eaat6420.
Indirect Elisa Protocol
N
- -
- -

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.